Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8,629 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.
Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Anderson LD Jr, Nathwani N, Shah N, Bumma N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Dinner S, Pei H, Cortoos A, Patel S, Lin TS, Usmani SZ, Richardson PG. Voorhees PM, et al. Among authors: shah n. Lancet Haematol. 2023 Oct;10(10):e825-e837. doi: 10.1016/S2352-3026(23)00217-X. Epub 2023 Sep 11. Lancet Haematol. 2023. PMID: 37708911 Clinical Trial.
Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma.
Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Orlowski RZ, Thomas SK, Shah J, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Bashir Q, et al. Among authors: shah j, shah n. Leuk Lymphoma. 2012 Jan;53(1):118-22. doi: 10.3109/10428194.2011.606942. Epub 2011 Aug 24. Leuk Lymphoma. 2012. PMID: 21780997
A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.
Sharma M, Khan H, Thall PF, Orlowski RZ, Bassett RL Jr, Shah N, Bashir Q, Parmar S, Wang M, Shah JJ, Hosing CM, Popat UR, Giralt SA, Champlin RE, Qazilbash MH. Sharma M, et al. Among authors: shah n, shah jj. Cancer. 2012 May 1;118(9):2507-15. doi: 10.1002/cncr.26517. Epub 2011 Sep 1. Cancer. 2012. PMID: 21887685 Free PMC article. Clinical Trial.
Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma.
Bashir Q, Khan H, Orlowski RZ, Amjad AI, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Thomas SK, Shah JJ, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Bashir Q, et al. Among authors: shah n, shah jj. Am J Hematol. 2012 Mar;87(3):272-6. doi: 10.1002/ajh.22273. Epub 2012 Jan 9. Am J Hematol. 2012. PMID: 22231283 Free PMC article.
Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma.
Sasaki K, Lu G, Saliba RM, Bashir Q, Hosing C, Popat U, Shah N, Parmar S, Dinh Y, Ahmed S, Shpall EJ, Kebriaei P, Shah JJ, Orlowski RZ, Champlin R, Qazilbash MH. Sasaki K, et al. Among authors: shah n, shah jj. Biol Blood Marrow Transplant. 2013 Aug;19(8):1227-32. doi: 10.1016/j.bbmt.2013.05.017. Epub 2013 May 31. Biol Blood Marrow Transplant. 2013. PMID: 23733001 Free PMC article.
A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma.
Bashir Q, Khan H, Thall PF, Liu P, Shah N, Kebriaei P, Parmar S, Oran B, Ciurea S, Nieto Y, Jones R, Hosing CM, Popat UR, Dinh YT, Rondon G, Orlowski RZ, Shah JJ, De Lima M, Shpall E, Champlin R, Giralt S, Qazilbash MH. Bashir Q, et al. Among authors: shah n, shah jj. Biol Blood Marrow Transplant. 2013 Oct;19(10):1453-8. doi: 10.1016/j.bbmt.2013.07.008. Epub 2013 Jul 17. Biol Blood Marrow Transplant. 2013. PMID: 23872222 Free PMC article. Clinical Trial.
Inflammatory markers and development of symptom burden in patients with multiple myeloma during autologous stem cell transplantation.
Wang XS, Shi Q, Shah ND, Heijnen CJ, Cohen EN, Reuben JM, Orlowski RZ, Qazilbash MH, Johnson VE, Williams LA, Mendoza TR, Cleeland CS. Wang XS, et al. Among authors: shah nd. Clin Cancer Res. 2014 Mar 1;20(5):1366-74. doi: 10.1158/1078-0432.CCR-13-2442. Epub 2014 Jan 14. Clin Cancer Res. 2014. PMID: 24423611 Free PMC article.
Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma.
Glitza IC, Lu G, Shah R, Bashir Q, Shah N, Champlin RE, Shah J, Orlowski RZ, Qazilbash MH. Glitza IC, et al. Among authors: shah j, shah r, shah n. Leuk Lymphoma. 2015 Mar;56(3):602-7. doi: 10.3109/10428194.2014.924116. Epub 2014 Aug 18. Leuk Lymphoma. 2015. PMID: 24844357 Free PMC article.
8,629 results